Article Data

  • Views 1456
  • Dowloads 143

Original Research

Open Access

Thrombosis in newborns: experience from 31 cases


1,Department of Neonatology Division of Paediatrics University Medical Centre Ljubljana

2,Department of Paediatric Surgery and Intensive Care University Medical Centre Ljubljana

DOI: 10.22514/SV72.102012.5 Vol.7,Issue 2,October 2012 pp.29-32

Published: 29 October 2012

*Corresponding Author(s): GREGOR NOSAN E-mail:


Thrombosis is the result of congenital or acquired prothrombotic risk factors. The incidence of thrombosis in the paediatric population is highest in newborns, as about 10% of thrombotic events occur in the first four weeks of life. Haemostasis in a newborn, though still developing, is a well balanced mechanism. About 90% of all thrombotic events are due to acquired and the rest to congenital risk factors. 

The aim of our study was to estimate the incidence of thrombosis in a population of Slovenian newborns and to study risk factors, location and treatment of thrombotic events. 

Inpatient charts of newborns with thrombosis, admitted to a tertiary neonatology centre and paediatric intensive care unit between 2004 and 2011, were studied retrospectively. Family history, location, aetiology and treatment of thrombosis were analysed. 

Thirty one newborns, 17 boys (54.8%) and 14 girls (45.2%), with 31 thrombotic events were found. There were 17 cases (54.8%) of arterial and 14 cases (45.2%) of venous thrombosis. A family history of thrombophilia was found in two cases (6.5%). Twenty six cases (83.9%) were contributed to acquired risk factors and five (16.1%) to congenital aetiology. Four cases (12.8%) were treated, two with anticoagulation, one with thrombolysis and one with both. The estimated incidence of thrombosis was 0.17 per 1000 live births. Our data showed a higher incidence of thrombosis in Slovenian newborns and a higher incidence of congenital prothrombotic risk factors than in the data published so far.


newborn, thrombosis, incidence, risk factor, treatment

Cite and Share

GREGOR NOSAN,MOJCA GROSELJ-GRENC,DARJA PARO-PANJAN. Thrombosis in newborns: experience from 31 cases. Signa Vitae. 2012. 7(2);29-32.


1. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediat Hematol Oncol 1990;12:95-104.

2. The British Committee for Standards in Haematology. Guidelines on the investigation and management of thrombophilia. J Clin Pathol 1990;43:703-9.

3. Andrew M. Developmental hemostasis: Relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995;74:415-25.

4. Hoppe C, Matsunaga A. Pediatric Thrombosis. Pediatric Clin of North America 2002; 49:1257-83.

5. García de Frutos P. Mechanisms of thrombophilia. Thromb Haemost 2007;98:485-7.

6. Nowak-Göttl U, von Kries R, Gobel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed 1997;76:163-7.

7. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995;96:939-43.

8. Göpel W, Kim D, Gortner L. Prothrombotic mutations as a risk factor for preterm birth. Lancet 1999;353:1411-2.

9. von Kries R, Junker R, Oberle D, Nowak-Göttl U. Foetal growth restriction in children with prothrombotic risk factors. Thromb Haemost 2001;86:1012-6.

10. Verspyck E, Borg JY, Le Cam-Duchez V, Goffinet F, Degré S, Fournet P, et al. Thrombophilia and fetal growth restriction. Eur J Obstet Gynecol Reprod Biol 2004;113:36-40.

11. Arsan S, Atasay B, Akar N. Thrombophilia and neonatal complications in preterm infants. Thromb Haemost 2004;92:212-3.

12. Khan S, Dickerman JD. Hereditary thrombophilia. Thromb J 2006;4:15.

13. Feero WG. Genetic Thrombophilia. Primary Care 2004;31:685-709.

14. Thornburg C, Pipe S. Neonatal thromboembolic emergencies. Semin Fetal Neonatal Med 2006;11:198-206.

15. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD. Antithrombotic therapy in children: the Seventh ACCP Conference on Anti-thrombotic and Thrombolytic Therapy. Chest 2004;126:645-87.

16. John CM, Harkensee C. Thrombolytic agents for arterial and venous thromboses in neonates. Cochrane Database Syst Rev 2005;25(1):CD004342.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 1.0 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time